Here, we present a case of relapsed GNET/CCS with EWSR1-CREB1 fusion, managed with combined nivolumab and cabozantinib. This evidence concerns the gene EWSR1 and gastric neuroendocrine tumor, well differentiated, low or intermediate grade.